Amprion Strategic Collaboration
Innovative testing
Through this strategic collaboration, Mayo Clinic Laboratories offers access to Amprion’s SAAmplify™–αSYN (CSF) assay, the only commercially available seed amplification test for detecting synucleinopathies. This advanced technology enables earlier and more accurate diagnosis of Parkinson’s disease, Lewy body dementia, and related disorders.
Collaborative expertise
Our strategic collaboration combines Mayo Clinic Laboratories’ leadership in diagnostic testing with Amprion’s pioneering approach to neurodegenerative disease biomarkers. Together, we deliver solutions that empower healthcare providers with actionable insights for patient care.
Patient-centered impact
Early detection means earlier intervention. By expanding access to SAAmplify™–αSYN testing, we help clinicians make informed decisions that improve outcomes and quality of life for patients facing neurodegenerative conditions.
“By combining Mayo Clinic Laboratories' expertise with Amprion's innovative technology, we are enhancing our ability to deliver precise and timely answers to patients and healthcare providers.”
William Morice II, M.D., Ph.D., President and CEO, Mayo Clinic Laboratories
The latest
SAAmplify™-αSYN testing offers unprecedented accuracy in diagnosing Parkinson’s and Lewy body dementia.
Join us for a webinar exploring the revolutionary way SAAmplify™–αSYN testing, which is offered by Mayo Clinic Laboratories in collaboration with Amprion, is improving diagnostic accuracy for patients with neurodegenerative disorders.
For healthcare professionals seeking to enhance their understanding of the assessment and treatment options for patients with neurodegenerative diseases.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test.
Mayo Clinic Laboratories and Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced a collaboration to expand access to Amprion's SAAmplify–αSYN (CSF) test across the United States. The test (test ID ASYNC) is available today for clients of Mayo Clinic Laboratories through the collaboration that combines the expertise of both organizations to enhance patient care and improve diagnostic accuracy for neurodegenerative diseases.